In a regulatory filing, Iovance Biotherapeutics disclosed that its director Merrill McPeak bought 250K shares of common stock on February 20th in a total transaction size of $2.29M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IOVA:
- Iovance Biotherapeutics Launches Share Sale for Drug Development
- Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
- Iovance Biotherapeutics’ AMTAGVI® Wins FDA Accelerated Approval
- Iovance (NASDAQ:IOVA): FDA Approves Cell Therapy, Stock Gains
- Iovance Biotherapeutics jumps 19% following conference call regarding Amtagvi
